

**Provider Partners Health Plan  
2022 Formulary – Step Therapy Criteria**

## **DEXILANT**

---

### **Products Affected**

**Step 2:**

- DEXILANT CAPSULE DELAYED RELEASE 30 MG ORAL
- DEXILANT CAPSULE DELAYED RELEASE 60 MG ORAL

### **Details**

---

<b>Criteria</b>	
	Claim will pay automatically for Dexilant if enrollee has a paid claim for at least a 1 day supply of esomeprazole, lansoprazole, omeprazole or pantoprazole in the past 365 days. Otherwise, Dexilant requires a step therapy exception request indicating: (1) history of inadequate treatment response with esomeprazole, lansoprazole, omeprazole or pantoprazole, OR (2) history of adverse event with esomeprazole, lansoprazole, omeprazole or pantoprazole, OR (3) esomeprazole, lansoprazole, omeprazole or pantoprazole is contraindicated.

**Y0135\_ST22\_C**  
**Formulary ID:22434\_Version 19**  
**Last Updated: 11/28/2022**  
**Effective Date: 12/01/2022**

**Provider Partners Health Plan  
2022 Formulary – Step Therapy Criteria**

## **DIFICID**

---

### **Products Affected**

**Step 2:**

- DIFICID SUSPENSION RECONSTITUTED 40 MG/ML ORAL
- DIFICID TABLET 200 MG ORAL

### **Details**

---

<b>Criteria</b>	
	Claim will pay automatically for Dificid if enrollee has a paid claim for at least a 1 day supply of vancomycin or Firvanq in the past 120 days. Otherwise, Dificid requires a step therapy exception request indicating: (1) history of inadequate treatment response with vancomycin or Firvanq, OR (2) history of adverse event with vancomycin or Firvanq, OR (3) vancomycin or Firvanq is contraindicated.

---

**Provider Partners Health Plan  
2022 Formulary – Step Therapy Criteria**

## **RYTARY**

---

### **Products Affected**

**Step 2:**

- RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL

### **Details**

---

<b>Criteria</b>	Claim will pay automatically for Rytary if enrollee has a paid claim for at least a 1 day supply of any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone in the past 365 days. Otherwise, Rytary requires a step therapy exception request indicating: (1) history of inadequate treatment response with any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone OR (2) history of adverse event with any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone, OR (3) any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone is contraindicated.
-----------------	--

**Y0135\_ST22\_C**  
**Formulary ID:22434\_Version 19**  
**Last Updated: 11/28/2022**  
**Effective Date: 12/01/2022**

# Provider Partners Health Plan 2022 Formulary – Step Therapy Criteria

## Index

### D

DEXILANT CAPSULE DELAYED RELEASE 30 MG ORAL.....	1
DEXILANT CAPSULE DELAYED RELEASE 60 MG ORAL.....	1
DIFICID SUSPENSION RECONSTITUTED 40 MG/ML ORAL	2
DIFICID TABLET 200 MG ORAL .....	2

### R

RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL .....	3
RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL .....	3
RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL .....	3
RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL .....	3